SPYH:F:F-SSgA SPDR ETFs Europe II Public Limited Company - SPDR MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 207.25

Change

-5.15 (-2.42)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

+36.80 (+7.43%)

USD 108.00B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+2.23 (+4.92%)

USD 105.67B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+2.26 (+4.53%)

USD 104.83B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.80 (+5.94%)

USD 62.86B
VUSA:F Vanguard Funds Public Limited ..

+7.35 (+8.43%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+10.50 (+5.18%)

USD 49.04B
XJSE:F Xtrackers II - Japan Governmen..

-0.18 (-2.40%)

USD 41.48B
0ZC:F Zscaler Inc

-15.48 (-9.11%)

USD 37.92B
BSND:F Danone SA

-0.20 (-1.45%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

N/A

USD 24.77B

ETFs Containing SPYH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.02% 45% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.02% 44% F 54% F
Trailing 12 Months  
Capital Gain -2.03% 27% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.03% 25% F 44% F
Trailing 5 Years  
Capital Gain 40.39% 41% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.39% 41% F 33% F
Average Annual (5 Year Horizon)  
Capital Gain 9.39% 66% D+ 63% D
Dividend Return 9.39% 63% D 55% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.97% 76% C+ 94% A
Risk Adjusted Return 117.91% 97% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike